Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by L. Capo
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
Cancer Research
Cancer Research
Oncology
Related publications
Targeting Nectin-4 in Bladder Cancer
Cancer Discovery
Oncology
Preclinical Evaluation of a GFRA1 Targeted Antibody-Drug Conjugate in Breast Cancer
Oncotarget
Oncology
A Novel Highly Potent Therapeutic Antibody Neutralizes Multiple Human Chemokines and Mimics Viral Immune Modulation
PLoS ONE
Multidisciplinary
Antibody-Drug Conjugates With HER2-targeting Antibodies From Synthetic Antibody Libraries Are Highly Potent Against HER2-positive Human Gastric Tumor in Xenograft Models
mAbs
Allergy
Immunology
MORAb-202, an Antibody Drug Conjugate Utilizing Humanized Anti-Human FRa Farletuzumab and the Microtubule-Targeting Agent Eribulin, Has Potent Anti-Tumor Activity
Molecular Cancer Therapeutics
Cancer Research
Oncology
An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity Against a Broad Range of Solid Tumors
Cancer Research
Cancer Research
Oncology
Successful Rapid Desensitization to the Antibody–drug Conjugate Brentuximab Vedotin in a Patient With Refractory Hodgkin Lymphoma
Journal of Oncology Pharmacy Practice
Medicine
Oncology
Pharmacology
Therapeutic Mechanism and Efficacy of the Antibody-Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9
Molecular Cancer Therapeutics
Cancer Research
Oncology
SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer
Molecular Cancer Therapeutics
Cancer Research
Oncology
